WO2009128088A2 - Preparation of 2-(2-alkoxy phenoxy) ethylamine, an intermediate of carvedilol and tamsulosin - Google Patents

Preparation of 2-(2-alkoxy phenoxy) ethylamine, an intermediate of carvedilol and tamsulosin Download PDF

Info

Publication number
WO2009128088A2
WO2009128088A2 PCT/IN2008/000725 IN2008000725W WO2009128088A2 WO 2009128088 A2 WO2009128088 A2 WO 2009128088A2 IN 2008000725 W IN2008000725 W IN 2008000725W WO 2009128088 A2 WO2009128088 A2 WO 2009128088A2
Authority
WO
WIPO (PCT)
Prior art keywords
formula
phenoxy
alkali metal
phthalimide
ethylamine
Prior art date
Application number
PCT/IN2008/000725
Other languages
French (fr)
Other versions
WO2009128088A3 (en
Inventor
Thota Giridhar
Gudipati Srinivasulu
Kotaru Srinivasa Rao
Original Assignee
Shodhana Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shodhana Laboratories Limited filed Critical Shodhana Laboratories Limited
Publication of WO2009128088A2 publication Critical patent/WO2009128088A2/en
Publication of WO2009128088A3 publication Critical patent/WO2009128088A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/02Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/36Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
    • C07C303/40Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/80[b, c]- or [b, d]-condensed
    • C07D209/82Carbazoles; Hydrogenated carbazoles
    • C07D209/88Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system

Definitions

  • the present patent application relates to a process for the preparation of 2-(2-Alkoxy phenoxy) ethylamine or a salt thereof, which is a useful intermediate in the preparation of several active pharmaceutical ingredients including Carvedilol and Tamsulosin.
  • 2-(2-Alkoxy phenoxy) ethylamine is chemically represented by the structural Formula I and is a useful intermediate in the preparation of several active pharmaceutical ingredients including Carvedilol and Tamsulosin.
  • Carvedilol is a non- selective beta blocker indicated in the treatment of mild to moderate congestive heart failure (CHF), hyper tension (high blood pressure), angina and is marketed under various trade names including Coreg (GSK), Dilatrend (Roche) and Eucardic (Roche). Carvedilol is chemically represented by the following structural Formula II
  • U.S. Patent. No. 4,503,067 discloses a process for preparing Carvedilol and its salts by the reaction of 4-(oxiran-2-ylmethoxy)-9H- carbazole with 2-(2-Methoxy phenoxy) ethylamine.
  • Tamsulosin an antagonist of alphalA adrenoceptors in the prostate, is chemically described as (-)-(i?)-5-[2-[[2-(o-Ethoxyphenoxy) ethyl]amino]propyl]-2- methoxybenzenesulfonamide and represented by the structural formula III
  • U.S. Patent No. 4,731,478 discloses Tamsulosin, its derivatives and salts along with processes for their preparation using 2-(2- ethoxyphenoxy) ethylamine.
  • Methoxy phenoxy) ethylamine that involves reaction of l -bromo-2-(2- methoxy phenoxy) ethane with potassium Phthalimide in Dimethyl formamide (DMF) and the Phthalimide derivative was then treated with hydrazine hydrate. Hydrazine hydrate is believed to be toxic, corrosive and hazardous substance which is not suitable for commercial manufacturing.
  • WO 99/51576 discloses a process for synthesis of 2-(2-Methoxy phenoxy) ethylamine that involves reacting Guaiacol with Bromo-acetonitrile in presence of NaH and DMF, which is further reacted with Lithium aluminium hydride (LiAlH 4 ) in presence of ethyl ether.
  • LiAlH 4 Lithium aluminium hydride
  • the present application provides a process for preparation of 2-(2-Alkoxy phenoxy) ethylamine of Formula I
  • Formula I wherein R is C1 -C4 alkyl, comprising the steps of: a) reacting 2-alkoxy phenol of Formula IV with 1,2-dihalo ethane to obtain l-halo-2-(2-alkoxy phenoxy) ethane of Formula V;
  • Formula IV Formula V Wherein R is C1-C4 alkyl; and X is F, Cl, Br, I; b) reacting l-halo-2-(2-alkoxy phenoxy) ethane of Formula V with an alkali metal salt of Phthalimide or substituted Phthalimide of Formula VI to form compound of Formula VII; and
  • Formula VI wherein R is C1-C4 alkyl; R 1 is H or C1-C4 alkyl, M is Na, K or any alkali metal c) reacting compound of Formula VII with a base comprising alkali metal hydroxide.
  • each step may be contemplated individually or combination of two steps.
  • the present invention provides a process for the preparation of 2-(2-methoxyphenoxy)ethylamine of Formula 1 in solid form.
  • the present application relates to use of 2-(2- Alkoxy phenoxy) -ethylamine or salt there of in the synthesis of active pharmaceutical ingredients including Carvedilol and Tamsulosin.
  • Fig 1 is an illustrative DSC thermogram of 2-(2-methoxy phenoxy)ethylamine in solid form obtained according to Example 4.
  • Fig 2 is an illustrative Infrared spectrum (IR) of 2-(2-methoxy phenoxy)ethylamine in solid form obtained according to Example 4.
  • the present patent application relates to a process for the preparation of 2-(2-Alkoxy phenoxy) ethylamine or a salt thereof, which is a useful intermediate in the preparation of several active pharmaceutical ingredients.
  • the present application provides a process for preparation of 2-(2-Alkoxy phenoxy) ethylamine of Formula I
  • Formula 1 wherein R is C1-C4 alkyl, comprising the steps of: a) reacting 2-alkoxy phenol of Formula IV with 1,2-dihalo ethane to obtain l-halo-2-(2-alkoxy phenoxy) ethane of Formula V;
  • Formula IV Formula V wherein R is C1-C4 alkyl; and X is F, Cl, Br, I; b) reacting l-halo-2-(2-methoxy phenoxy) ethane of Formula V with an alkali metal salt of Phthalimide or substituted Phthalimide of Formula VI to form compound of Formula VII; and
  • Formula VI wherein R is C1-C4 alkyl; Ri is H or C1-C4 alkyl, M is Na, K or any alkali metal c) reacting compound of Formula VII with a base comprising alkali metal hydroxide.
  • Step a) involves 2-alkoxy phenol of Formula IV with 1,2-dihalo ethane.
  • 2-alkoxy phenol includes C1-C4 alkoxy phenols, preferably 2- methoxy phenol and 2-ethoxy phenol.
  • 1,2-Dihaloethane is selected form 1,2-dichloroethane, 1,2- dibromoethae and the like. 1,2-dichloroethane is preferred.
  • the reaction may be carried out with or without an external solvent.
  • the 1, 2- dihaloethane acts both as reagent and solvent.
  • the reaction is carried out in the presence of a base.
  • Suitable base that can be used include alkali metal hydroxides such as sodium hydroxide, potassium hydroxide and the like.
  • the reaction of step a) may be carried out in the presence of a phase transfer catalyst.
  • Suitable phase transfer catalyst includes but is not limited to tetra butyl ammonium bromide(TBAB), methyltrioctylammonium chloride, potassium bromide, and the like.
  • Tetra butyl ammonium bromide is preferred.
  • Suitable temperatures for conducting the reaction can range from about 25°C to about reflux temperature of the solvent used, preferably reflux temperature of the solvent used.
  • the reaction can be conducted till the completion of the reaction.
  • the reaction time varies from about 1 hour to about 15 hours.
  • the organic layer containing the ; product may be separated, washed with water and proceeds to next step directly or it can be distilled to obtain the product as residue.
  • the l-halo-2-(2-alkoxy phenoxy) ethane obtained as residue may be purified by using suitable techniques including high vacuum distillation.
  • Step b) involves reacting l-halo-2-(2-alkoxy phenoxy) ethane of Formula V with an alkali metal salt of Phthalimide or substituted Phthalimide of Formula VI to form the compound of Formula VII.
  • Phthalimide derivative or an alkali metal salt that can be used include alkali metal salt of Phthalimide or a substituted Phthalimide such as sodium phthalimide, potassium phthalimide, sodium or potassium salt of methyl or ethyl phthalimide, preferably potassium phthalimide.
  • the reaction of step b) may also be carried out in the presence of phase transfer catalyst.
  • phase transfer catalyst includes but is not limited to tetra butyl ammonium bromide, methyltrioctylammonium chloride, potassium bromide, and the like. Tetra b ⁇ tyl ammonium bromide is preferred.
  • the reaction can be carried out with or without an external solvent. Preferably the reaction is carried out with out an external solvent.
  • Suitable temperatures for conducting the reaction can range from about 50°C to about 250 0 C, preferably from about 180°C to about 190
  • the reaction can be conducted till the completion of the reaction.
  • reaction time varies from about 30 minutes to about 5 hours.
  • the molar ratio of l-halo-2-(2-alkoxy phenoxy) ethane to Phthalimide derivative can range from about 1:0.5 to about 1:5.
  • reaction mixture is quenched with water and processed using suitable techniques for precipitation of the solid.
  • the solid product thus obtained may be further purified by methods such as precipitation, crystallization or slurrying in a solvent.
  • Solvents that may be used for such purposes include, but are not limited to alcohols such as methanol, ethanol, isopropanol and the like; esters such as ethyl acetate, n-propylacetate, isopropyl acetate and the like; ketones such as acetone, ethyl methyl ketone and the like; acetonitrile, water or mixtures thereof.
  • the solid product is recovered by suitable techniques such as decantation, filtration by gravity or by suction, centrifugation, and the like. Other techniques for separating the solids from the reaction mixtures are also within the scope of this invention.
  • the process may include further drying of the product obtained with or without vacuum and in presence or absence of inert atmosphere.
  • Step c) involves reacting compound of Formula VII with a base comprising alkali metal hydroxide.
  • Suitable bases that can be used include alkali metal hydroxide such as sodium hydroxide, potassium hydroxide and the like
  • alkali metal hydroxide such as sodium hydroxide, potassium hydroxide and the like
  • Alkali metal hydroxide may be used in the form of solid or as a solution obtained by dissolving alkali metal hydroxide in water.
  • Reaction may be conducted without an additional solvent, when alkali metal hydroxide solution is used or solvents such as water may be used.
  • Suitable temperatures for conducting the reaction can range from about 50 0 C to about 250 0 C, preferably from about 100 0 C to about 120 0 C.
  • the reaction can be conducted till the completion of the reaction. Typically the reaction time varies from about 1 hour to about 15 hours.
  • the molar ratio of compound of Formula VII to alkali metal hydroxide can range from about 1 : 1 to about 1 : 10.
  • the reaction mixture is quenched with water and processed using suitable techniques for precipitation of the solid.
  • the solid product is recovered by suitable techniques such as - decantation, filtration by gravity or by suction, ccnt ⁇ fugation, and he " - like.
  • the product may be further dried. Drying can be carried out in a % tray dryer, vacuum oven, air oven, fluidized bed drier, spin flash dryer at - founded temperatures of about 35°C to about 70°C with or without vacuum.
  • the 2-(2- alkoxy-phenoxy) ethylamine of Formula 1 is prepared in solid form . having melting range from about 80 0 C to 90 0 C.
  • thermogram was recorded from 40 0 C to 150 0 C under the nitrogen flow of 50mL/min at a heating rate of 2°C/min
  • 2-(2-Methoxy- phenoxy) ethylamine is prepared from 2-methoxy phenol and 2-(2- ethoxy-phenoxy) ethylamine is prepared from 2-ethoxy phenol.
  • each step may be contemplated individually or combination of two steps.
  • the present application relates to use of 2-(2-aminoethyl)-2-(2-aminoethyl)-2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-(2-aminoethyl)-2-(2-aminoethyl)-2-(2-aminoethyl)-2-(2-aminoethyl)-2-aminoethyl)-2-(2-aminoethyl)-2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoeth
  • Alkoxy phenoxy)-ethylamine or a salt there of in the synthesis of active pharmaceutical ingredients including Carvedilol and Tamsulosin.
  • This process of the present application involves the usage of inexpensive, less hazardous and easily available raw materials and makes the process suitable for commercial manufacturing.
  • Example 5 Preparation of Carve dilol using 2-(2-methoxyphenoxy) ethylamine solid: In a dry reaction flask, 4-(2,3-epoxy propoxy) carbazole (50 gm), 2 7 (2- methoxy phenoxy) ethyl amine solid (75.5 gm) and 500 ml of ethyl acetate were charged and heated to reflux for about 24 hours. After completion of the reaction, solvent was distilled off from the reaction mixture to obtain 117 gm of the residue. Ethyl acetate ( 175 ml) was added to the residue and stirred for about 12 hours at room temperature. The suspension was cooled to O 0 C, filtered and dried to get 65 gm of the title compound. M.R: 115 °C- 1 17°C Purity by HPLC: 99.74%
  • Phthalimide derivative of l-(2-Chloroethoxy)-2-methoxy benzene was added to 50 ml 48 % aqueous sodium hydroxide solution (Caustic lye) in 50 ml of water. The contents were heated to about 130 0 C and stirred for about 13 hours. The reaction mixture was cooled and ambient temperature and charged 100 ml of toluene. The aqueous layer was separated and extracted with toluene (1 XlOO ml; 1 X50 ml) and dried the total organic layer with 20 gm of sodium chloride. The organic layer was distilled completely to obtain 21.5 gm of the title compound as residue.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present patent application relates to a process for the preparation of 2-(2-Alkoxy phenoxy) ethylamine or a salt thereof, which is a useful intermediate in the preparation of several active pharmaceutical ingredients including Carvedilol and Tamsulosin. It also provides 2-(2-methoxy phenoxy) ethylamine in solid form.

Description

PREPARATION OF 2-(2-ALKOXY PHENOXY) ETHYLAMINE, AN INTERMEDIATE OF CARVEDILOL AND T AMSULOSIN
FIELD The present patent application relates to a process for the preparation of 2-(2-Alkoxy phenoxy) ethylamine or a salt thereof, which is a useful intermediate in the preparation of several active pharmaceutical ingredients including Carvedilol and Tamsulosin.
BACKGROUND
2-(2-Alkoxy phenoxy) ethylamine is chemically represented by the structural Formula I and is a useful intermediate in the preparation of several active pharmaceutical ingredients including Carvedilol and Tamsulosin.
Figure imgf000002_0001
Formula I wherein R is C 1-C4 alkyl.
Carvedilol is a non- selective beta blocker indicated in the treatment of mild to moderate congestive heart failure (CHF), hyper tension (high blood pressure), angina and is marketed under various trade names including Coreg (GSK), Dilatrend (Roche) and Eucardic (Roche). Carvedilol is chemically represented by the following structural Formula II
Figure imgf000002_0002
Formula II U.S. Patent. No. 4,503,067 discloses a process for preparing Carvedilol and its salts by the reaction of 4-(oxiran-2-ylmethoxy)-9H- carbazole with 2-(2-Methoxy phenoxy) ethylamine.
Tamsulosin, an antagonist of alphalA adrenoceptors in the prostate, is chemically described as (-)-(i?)-5-[2-[[2-(o-Ethoxyphenoxy) ethyl]amino]propyl]-2- methoxybenzenesulfonamide and represented by the structural formula III
Figure imgf000003_0001
Formula III U.S. Patent No. 4,731,478 discloses Tamsulosin, its derivatives and salts along with processes for their preparation using 2-(2- ethoxyphenoxy) ethylamine.
From the abstract of CH 383998 it appears to describe a process for preparation of 2-alkoxyphenoxyethanamines in which liquid ammonia is reacted with 2-Methoxyphenoxyethylbromide in methanol. The mixture is heated for ten hours in an autoclave. This process leads to di & tri substituted amines as side products resulting in less yield. Complicated isolated procedure and the usage of liquid ammonia make the process expensive and not suitable for commercial manufacturing. U.S. Patent No. 3,412, 154 discloses a process for synthesis of 2-
(2-Methoxyphenoxy) ethylamine that involves the usage of toxic, corrosive and hazardous substance of chloroacetonitrile and pressurized catalytic hydrogenation in presence of Raney cobalt catalyst. This process results in high manufacturing cost and unsafe reaction procedures. U.S. Patent No. 3,474, 134 discloses a process for synthesis of 2-(2-
Methoxy phenoxy) ethylamine that involves reaction of l -bromo-2-(2- methoxy phenoxy) ethane with potassium Phthalimide in Dimethyl formamide (DMF) and the Phthalimide derivative was then treated with hydrazine hydrate. Hydrazine hydrate is believed to be toxic, corrosive and hazardous substance which is not suitable for commercial manufacturing.
International Application publication No. WO 99/51576 discloses a process for synthesis of 2-(2-Methoxy phenoxy) ethylamine that involves reacting Guaiacol with Bromo-acetonitrile in presence of NaH and DMF, which is further reacted with Lithium aluminium hydride (LiAlH4) in presence of ethyl ether. The usage of reagents such as NaH and LiAlH4 are hazardous and not suitable for safe commercial manufacturing.
International Application publication No. WO 03/095416 discloses a synthesis of 2-(2-alkoxy phenoxy) ethylamine by the reaction of ortho substituted phenol with a 2-Alkyloxyoxazoline.
2-(2-alkoxy phenoxy) ethylamine prepared according to the above mentioned processes was obtained in the form of liquid which is difficult to store and further more difficult to handle.
Consequently, it would be a contribution to the art to provide a scalable, highly pure and safe process for the preparation of 2-(2-Alkoxy; phenoxy) ethylamine and its salts using commercially available raw- materials SUMMARY OF THE INVENTION
In one aspect the present application provides a process for preparation of 2-(2-Alkoxy phenoxy) ethylamine of Formula I
Figure imgf000004_0001
Formula I wherein R is C1 -C4 alkyl, comprising the steps of: a) reacting 2-alkoxy phenol of Formula IV with 1,2-dihalo ethane to obtain l-halo-2-(2-alkoxy phenoxy) ethane of Formula V;
Figure imgf000004_0002
Formula IV Formula V Wherein R is C1-C4 alkyl; and X is F, Cl, Br, I; b) reacting l-halo-2-(2-alkoxy phenoxy) ethane of Formula V with an alkali metal salt of Phthalimide or substituted Phthalimide of Formula VI to form compound of Formula VII; and
Figure imgf000005_0001
Formula VI Formula VII wherein R is C1-C4 alkyl; R1 is H or C1-C4 alkyl, M is Na, K or any alkali metal c) reacting compound of Formula VII with a base comprising alkali metal hydroxide.
In this multi step process, each step may be contemplated individually or combination of two steps.
In another aspect, the present invention provides a process for the preparation of 2-(2-methoxyphenoxy)ethylamine of Formula 1 in solid form.
In another aspect the present application relates to use of 2-(2- Alkoxy phenoxy) -ethylamine or salt there of in the synthesis of active pharmaceutical ingredients including Carvedilol and Tamsulosin.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig 1 is an illustrative DSC thermogram of 2-(2-methoxy phenoxy)ethylamine in solid form obtained according to Example 4.
Fig 2 is an illustrative Infrared spectrum (IR) of 2-(2-methoxy phenoxy)ethylamine in solid form obtained according to Example 4.
DETAILED DESCRIPTION OF THE INVENTION
The present patent application relates to a process for the preparation of 2-(2-Alkoxy phenoxy) ethylamine or a salt thereof, which is a useful intermediate in the preparation of several active pharmaceutical ingredients.
In one aspect the present application provides a process for preparation of 2-(2-Alkoxy phenoxy) ethylamine of Formula I
Figure imgf000006_0001
Formula 1 wherein R is C1-C4 alkyl, comprising the steps of: a) reacting 2-alkoxy phenol of Formula IV with 1,2-dihalo ethane to obtain l-halo-2-(2-alkoxy phenoxy) ethane of Formula V;
Figure imgf000006_0002
Formula IV Formula V wherein R is C1-C4 alkyl; and X is F, Cl, Br, I; b) reacting l-halo-2-(2-methoxy phenoxy) ethane of Formula V with an alkali metal salt of Phthalimide or substituted Phthalimide of Formula VI to form compound of Formula VII; and
Figure imgf000006_0003
Formula VI Formula VII wherein R is C1-C4 alkyl; Ri is H or C1-C4 alkyl, M is Na, K or any alkali metal c) reacting compound of Formula VII with a base comprising alkali metal hydroxide.
Step a) involves 2-alkoxy phenol of Formula IV with 1,2-dihalo ethane.
2-alkoxy phenol includes C1-C4 alkoxy phenols, preferably 2- methoxy phenol and 2-ethoxy phenol. 1,2-Dihaloethane is selected form 1,2-dichloroethane, 1,2- dibromoethae and the like. 1,2-dichloroethane is preferred. The reaction may be carried out with or without an external solvent. Suitably the 1, 2- dihaloethane acts both as reagent and solvent. Suitably the reaction is carried out in the presence of a base.
Suitable base that can be used include alkali metal hydroxides such as sodium hydroxide, potassium hydroxide and the like.
In one variant, the reaction of step a) may be carried out in the presence of a phase transfer catalyst. Suitable phase transfer catalyst includes but is not limited to tetra butyl ammonium bromide(TBAB), methyltrioctylammonium chloride, potassium bromide, and the like.
Tetra butyl ammonium bromide is preferred.
Suitable temperatures for conducting the reaction can range from about 25°C to about reflux temperature of the solvent used, preferably reflux temperature of the solvent used. The reaction can be conducted till the completion of the reaction. Typically the reaction time varies from about 1 hour to about 15 hours.
After completion of the reaction, the organic layer containing the ; product may be separated, washed with water and proceeds to next step directly or it can be distilled to obtain the product as residue.
In one embodiment the l-halo-2-(2-alkoxy phenoxy) ethane obtained as residue may be purified by using suitable techniques including high vacuum distillation.
Step b) involves reacting l-halo-2-(2-alkoxy phenoxy) ethane of Formula V with an alkali metal salt of Phthalimide or substituted Phthalimide of Formula VI to form the compound of Formula VII.
Phthalimide derivative or an alkali metal salt that can be used include alkali metal salt of Phthalimide or a substituted Phthalimide such as sodium phthalimide, potassium phthalimide, sodium or potassium salt of methyl or ethyl phthalimide, preferably potassium phthalimide.
In one embodiment, the reaction of step b) may also be carried out in the presence of phase transfer catalyst. Suitable phase transfer catalyst includes but is not limited to tetra butyl ammonium bromide, methyltrioctylammonium chloride, potassium bromide, and the like. Tetra bμtyl ammonium bromide is preferred.
The reaction can be carried out with or without an external solvent. Preferably the reaction is carried out with out an external solvent.
Suitable temperatures for conducting the reaction can range from about 50°C to about 250 0C, preferably from about 180°C to about 190
°C. The reaction can be conducted till the completion of the reaction.
Typically the reaction time varies from about 30 minutes to about 5 hours.
The molar ratio of l-halo-2-(2-alkoxy phenoxy) ethane to Phthalimide derivative can range from about 1:0.5 to about 1:5.
After completion of the reaction, the reaction mixture is quenched with water and processed using suitable techniques for precipitation of the solid.
The solid product thus obtained may be further purified by methods such as precipitation, crystallization or slurrying in a solvent. Solvents that may be used for such purposes include, but are not limited to alcohols such as methanol, ethanol, isopropanol and the like; esters such as ethyl acetate, n-propylacetate, isopropyl acetate and the like; ketones such as acetone, ethyl methyl ketone and the like; acetonitrile, water or mixtures thereof.
The solid product is recovered by suitable techniques such as decantation, filtration by gravity or by suction, centrifugation, and the like. Other techniques for separating the solids from the reaction mixtures are also within the scope of this invention. The process may include further drying of the product obtained with or without vacuum and in presence or absence of inert atmosphere.
Step c) involves reacting compound of Formula VII with a base comprising alkali metal hydroxide.
Suitable bases that can be used include alkali metal hydroxide such as sodium hydroxide, potassium hydroxide and the like Alkali metal hydroxide may be used in the form of solid or as a solution obtained by dissolving alkali metal hydroxide in water.
Reaction may be conducted without an additional solvent, when alkali metal hydroxide solution is used or solvents such as water may be used.
Suitable temperatures for conducting the reaction can range from about 500C to about 250 0C, preferably from about 1000C to about 120 0C. The reaction can be conducted till the completion of the reaction. Typically the reaction time varies from about 1 hour to about 15 hours. The molar ratio of compound of Formula VII to alkali metal hydroxide can range from about 1 : 1 to about 1 : 10.
After completion of the reaction, the reaction mixture is quenched with water and processed using suitable techniques for precipitation of the solid. The solid product is recovered by suitable techniques such as - decantation, filtration by gravity or by suction, ccntπfugation, and he "- like. The product may be further dried. Drying can be carried out in a % tray dryer, vacuum oven, air oven, fluidized bed drier, spin flash dryer at - „ temperatures of about 35°C to about 70°C with or without vacuum. In a more specific embodiment of the present invention, the 2-(2- alkoxy-phenoxy) ethylamine of Formula 1 is prepared in solid form . having melting range from about 800C to 900C.
Differential scanning calorimetric analysis reported herein was carried out on TAQ lOOO. The thermogram was recorded from 400C to 1500C under the nitrogen flow of 50mL/min at a heating rate of 2°C/min
In a specific embodiment of the present invention, 2-(2-Methoxy- phenoxy) ethylamine is prepared from 2-methoxy phenol and 2-(2- ethoxy-phenoxy) ethylamine is prepared from 2-ethoxy phenol.
The process of the present application is described in Scheme I.
Figure imgf000010_0001
Formula IV Formula V
Figure imgf000010_0002
Formula I
Formula VII
Scheme I
In this multi step process, each step may be contemplated individually or combination of two steps. In another aspect the present application relates to use of 2-(2-
Alkoxy phenoxy)-ethylamine or a salt there of in the synthesis of active pharmaceutical ingredients including Carvedilol and Tamsulosin.
This process of the present application involves the usage of inexpensive, less hazardous and easily available raw materials and makes the process suitable for commercial manufacturing.
Certain specific aspects and embodiments of the present application will be explained in more detail with reference to the following examples, which are provided by way of illustration only and should not be construed as limiting the scope of the invention in any manner.
Examples
Example 1 : Preparation of l-(2-Chloro ethoxy)-2-methoxy benzene
2-Methoxy phenol (200 kg) in 1000 L of 1,2-dichloroethane, 300 L of caustic lye and 14 kg of tetrabutyl ammonium bromide were heated to reflux and stirred for about for 16 hours. Cooled the reaction mixture to ambient temperature and separated the layers. Aqueous layer was extracted with dichloroethane (2 X 200 L). Total organic layer was washed with water and distilled off the solvent completely under the vacuum to get the residue (310 kg). The residue was further purified by high vacuum distillation to obtain 210 kg of pure l-(2-Chloro ethoxy)-2- methoxy benzene.
Example 2: Preparation of Phthalimide derivative of l-(2-Chloro- ethoxy)-2-methoxy-benzene
150 kg of pure l-(2-Chloro ethoxy)-2-methoxy benzene obtained according to the procedure described in Example 1, 195 kg of Potassium Phthalimide and 7.5 kg of tetrabutyl ammonium bromide were charged in a reactor and heated to about 180 °C and stirred for about 3 hours at about 180 °C to 185 °C. The reaction mixture was transferred in to a container having 1650 L of water and the precipitated solid was filtered. The wet material (300 kg) was charged into a reactor containing 300 L of methanol and heated to reflux. The contents were stirred at reflux for about 1 hour. The reaction mixture was cooled to ambient temperature and filtered the solid .The wet solid was dried at 60-80 0C to obtain 2-10 kg of the title compound.
Example 3: Preparation of 2-(2-Methoxy phenoxy) ethylamine
50 gm of potassium hydroxide was dissolved in 50 ml of water and 50 gm of Phthalimide derivative of l-(2-Chloroethoxy)-2-methoxy benzene was added to the solution. The contents were heated to about 130 0C and stirred for about 13 hours. The reaction mixture was cooled and ambient temperature and extracted with 2 X 200 ml of dichloromethane (DCM).
20 ml of 36% aqueous hydrochloric acid was added to the organic layer and stirred the contents for 15 minutes and separated the layers. The aqueous layer was washed with DCM (2 X 25 ml) and then pH was adjusted to about 8 using aqueous sodium hydroxide solution. The aqueous layer was extracted with toluene (2 XlOO ml) and distilled off the solvent completely to obtain 20 gm of the title compound as residue. Purity by HPLC: 98.05 % Example 4: Preparation of 2-(2-methoxyphenoxy) ethylamine in solid form:
Add 10 ml of water to 100 gm of crude 2-(2-methoxyphenoxy) ethylamine (obtained from the procedure of Example 3) and allowed the crude to dry for 36 hours to get the wet solid (100 gm). The wet solid (100 gm) was taken into round bottom flask and added (200 ml) of ethyl acetate and maintained for half an hour at room temperature. The solid was filtered, washed with 50 ml of ethyl acetate and dried to get 73.5 gm of the title compound in the form of solid. M.R: 84 °C - 870C
Purity by HPLC: 99.71%
Example 5: Preparation of Carve dilol using 2-(2-methoxyphenoxy) ethylamine solid: In a dry reaction flask, 4-(2,3-epoxy propoxy) carbazole (50 gm), 27(2- methoxy phenoxy) ethyl amine solid (75.5 gm) and 500 ml of ethyl acetate were charged and heated to reflux for about 24 hours. After completion of the reaction, solvent was distilled off from the reaction mixture to obtain 117 gm of the residue. Ethyl acetate ( 175 ml) was added to the residue and stirred for about 12 hours at room temperature. The suspension was cooled to O0C, filtered and dried to get 65 gm of the title compound. M.R: 115 °C- 1 17°C Purity by HPLC: 99.74%
Example 6: Preparation of 2-(2-Methoxy phenoxy) ethylamine using NaOH
50 gm of Phthalimide derivative of l-(2-Chloroethoxy)-2-methoxy benzene was added to 50 ml 48 % aqueous sodium hydroxide solution (Caustic lye) in 50 ml of water. The contents were heated to about 130 0C and stirred for about 13 hours. The reaction mixture was cooled and ambient temperature and charged 100 ml of toluene. The aqueous layer was separated and extracted with toluene (1 XlOO ml; 1 X50 ml) and dried the total organic layer with 20 gm of sodium chloride. The organic layer was distilled completely to obtain 21.5 gm of the title compound as residue.
Purity by HPLC: 98.74 %
Example 7: Preparation of l-(2-chloroethoxy)-2-ethoxy benzene
100 gm of 2-ethoxy phenol was added to 150ml of caustic lye dissolved in 450 ml of water at 25-35°C. 500 ml of 1,2-dichloroethane and 7 gm of TBAB was added to the above reaction mixture at 25-35°C and heated to reflux for about 16 hours. After completion, the reaction mixture was cooled to 25-350C and separated the layers. Aqueous layer was extracted with dichloroethane (2XlOOmI). Total organic layer was washed with 5% caustic lye and distilled off the solvent completely to get residue (140 gm). The residue was further purified by high vacuum distillation to get 112 gm of pure title compound.
Example 8: Preparation of phthalimide derivative of l-l-(2- chloroethoxy)-2-ethoxy benzene:
About 70 gm of l-(2-chloroethoxy)-2-ethoxy benzene obtained from Example 5, 91 gm of potassium phthalimide and 3.5 gm of TBAB were charged in a reactor and heated to 175-185°C and stirred for about 4 hours. The reaction mixture was cooled to about 80°C, 800 ml of water was added and cooled further to 25-35°C. The contents were stirred for about 2 hours, filtered the reaction mixture and washed with 200 ml of water to get 136 gm of wet solid. The wet material was dissolved in 200 ml of methanol, heated to reflux and maintained for about 30 minutes at 60-700C. Cooled the reaction mixture to 25-35°C and stirred for about 2 hours. The reaction mixture was filtered and washed with methanol. The wet solid was dried to get 98.5 gm of title compound.
Example 9: Preparation of 2-(2-ethoxy phenoxy) ethylamine:
About 50 gms of phthalimide derivative of l -l-(2-chloroethoxy)-2- ethoxy benzene obtained from Example 6, 50 gm of potassium hydroxide and 50 ml of water were charged in a flask. The contents were heated to reflux and maintained for about 6 hours. After completion of the reaction, the reaction mixture was cooled to room temperature and extracted with 200 ml of toluene. The organic layer was acidified with aqueous HCl and 250 ml of water was added to the organic layer. Separated the layers, the aqueous layer was basified with caustic lye and extracted into dichloromethane (300, 100, 100 ml.). The total organic layer was washed with water, dried with sodium sulfate and distilled off to remove the solvent completely to get 23 grams of the title compound as residue.
Example 10: Preparation of Phthalimide derivative of l-(2-Chloro- ethoxy)-2-methoxy -benzene.
50 gm of pure l-(2-Chloro ethoxy)-2-methoxy benzene obtained according to the procedure described in Example 1, 65 gm of Potassium Phthalimide and 2.5gm of tetra butyl ammonium bromide were charged in a flask and heated to about 1800C and stirred for about 3 hours at about 1800C to 185°C. The reaction mixture was cooled to below 1000 C, added 25 ml of methanol, maintained at reflux. Cool to room temperature and filtered the solid to obtain 63 gm of the title compound

Claims

Claims:
1. A process for preparation of 2-(2-Alkoxyoxy phenoxy) ethylamine of Formula I
Figure imgf000015_0001
Formula J wherein R is C1-C4 alkyl, comprising the steps of: a) reacting 2-alkoxy phenol of Formula IV with 1,2-dihalo ethane to obtain l-halo-2-(2-alkoxy phenoxy) ethane of Formula V;
Figure imgf000015_0002
Formula IV Formula V wherein R is C1-C4 alkyl; and X is F, Cl, Br, I; b) reacting l-halo-2-(2-methoxy phenoxy) ethane of Formula V with an alkali metal salt of Phthalimide or substituted Phthalimide of Formula VI to form compound of Formula VII; and
Figure imgf000015_0003
Formula VI Formula VII wherein R is C1-C4 alkyl; Ri is H or C1-C4 alkyl, M is Na, K or any alkali metal c) reacting compound of Formula VII with a base comprising alkali metal hydroxide.
2. The process of Claim 1 wherein 2-alkoxy phenol used in step a) includes 2-methoxy phenol and 2-ethoxy phenol.
3. The process of Claim 1 wherein 1 ,2-Dihaloethane used in step a) is selected form 1 ,2-dichloroethane and 1,2-dibromoethane.
4. The process of Claim 1 wherein the process of step a) is carried out in the presence of a base selected from alkali metal hydroxides such as sodium hydroxide, potassium hydroxide.
5. The process of Claim I wherein the process of step a) is carried out in the presence of a phase transfer catalyst selected from tetra butyl ammonium bromide and methyltrioctylammonium chloride
6. The process of Claim 1 wherein Phthalimide derivative or an alkali metal salt used in step b) is selected from sodium phthalimide, potassium phthalimide, sodium or potassium salt of methyl or ethyl phthalimide.
7. The process of Claim 1 wherein the process of step b) is carried out in the presence of a phase transfer catalyst selected from tetra butyl ammonium bromide and methyltrioctylammonium chloride,
8. The process of Claim 1 wherein the process of step b) is carried put with out any solvent.
9. The process of Claim 1 wherein the process of step b) is carried: out at temperatures from about 50°C to about 250 0C.
10. The process of Claim 1 wherein the molar ratio of l-halo-2-(2- methoxy phenoxy) ethane to Phthalimide derivative used in step b) range from about 1 :0.5 to about 1:5.
1 1. The process of Claim 1 wherein the process of step c) is carried out in the presence of a base selected from alkali metal hydroxide such as sodium hydroxide, potassium hydroxide.
12. The process of Claim 1 wherein the process of step c) is carried out without any additional organic solvent, when alkali metal hydroxide solution is used.
13. The process of Claim 1 wherein the process of step c) is carried out at temperatures from about 50°C to about 250 0C.
14. The process of Claim 1 wherein the molar ratio of compound of Formula VII to alkali metal hydroxide in step c) can range from about 1 : 1 to about 1 : 10.
15. The process of Claim 1 wherein the compound of formula I is obtained in the form of solid powder or oily residue.
16. A process for preparation of 2-(2-Alkoxy phenoxy) ethylamine of Formula I
Figure imgf000017_0001
Formula I wherein R is C1-C4 alkyl, comprising the steps of: a) reacting l-halo-2-(2-alkoxy phenoxy) ethane of Formula V with an alkali metal salt of Phthalimide or substituted Phthalimide of Formula VI to form compound of Formula VII; and
Figure imgf000017_0002
Formula VI Formula VII wherein R is C1-C4 alkyl; R1 is H or C1-C4 alkyl, M is Na, K or any alkali metal b) reacting compound of Formula VII with a base comprising alkali metal hydroxide.
16. A process for preparation of 2-(2-Alkoxy phenoxy) ethylamine of Formula I
Figure imgf000017_0003
Formula I wherein R is C1-C4 alkyl, comprises of reacting compound of Formula VII
Figure imgf000018_0001
with a base comprising alkali metal hydroxide.
18. A process for preparation of 2-(2-methoxy phenoxy) ethylamme comprising the steps of: a) reacting l-chloro-2-(2-methoxy phenoxy) ethane with potassium phthalimide; and b) reacting the product obtained in step a) with potassium hydroxide.
19. 2-(2-methoxy phenoxy) ethylamine in solid form.
20. A process for the preparation of Carvedilol or a salt there of using 2-(2-methoxy phenoxy) ethylamine in solid form
21. A process for preparation of 2-(2-ethoxy phenoxy) ethylamine comprising the steps of: a) reacting l -chloro-2-(2-ethoxy phenoxy) ethane with potassium phthalimide; and b) reacting the product obtained in step a) with potassium hydroxide.
22. A method of using of 2-(2-Alkoxy phenoxy) -ethylamine or s salt there of in the synthesis of active pharmaceutical ingredients including
Carvedilol and Tamsulosin.
PCT/IN2008/000725 2008-04-15 2008-11-03 Preparation of 2-(2-alkoxy phenoxy) ethylamine, an intermediate of carvedilol and tamsulosin WO2009128088A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN923CH2008 2008-04-15
IN923/CHE/2008 2008-04-15

Publications (2)

Publication Number Publication Date
WO2009128088A2 true WO2009128088A2 (en) 2009-10-22
WO2009128088A3 WO2009128088A3 (en) 2010-12-23

Family

ID=41199536

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2008/000725 WO2009128088A2 (en) 2008-04-15 2008-11-03 Preparation of 2-(2-alkoxy phenoxy) ethylamine, an intermediate of carvedilol and tamsulosin

Country Status (1)

Country Link
WO (1) WO2009128088A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109206328A (en) * 2018-09-27 2019-01-15 铜仁学院 A kind of preparation method of 2- (2- methoxyphenoxy) ethamine
CN115232034A (en) * 2022-07-29 2022-10-25 上药康丽(常州)药业有限公司 Method for synthesizing tamsulosin hydrochloride

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999051576A1 (en) * 1998-04-08 1999-10-14 American Home Products Corporation N-aryloxyethylamine derivatives for the treatment of depression
US20010056211A1 (en) * 1997-07-31 2001-12-27 Ing-Jun Chen Guaiacoxypropanolamines with alpha/beta adrenergic blocking activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010056211A1 (en) * 1997-07-31 2001-12-27 Ing-Jun Chen Guaiacoxypropanolamines with alpha/beta adrenergic blocking activity
WO1999051576A1 (en) * 1998-04-08 1999-10-14 American Home Products Corporation N-aryloxyethylamine derivatives for the treatment of depression

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A.M. LIU ET AL SYNTHESIS OF 2-(2-METHOXYPHENOXY)ETHYLAMINE pages 794 - 796 *
CHEN, WEIMIN ET AL: 'Synthesis of 2-(2- methoxyphenoxy)ethylamine by phase transfer catalysis and microwave radiation' HUAXUE SHIJIE vol. 39, no. 2, 1998, pages 86 - 87 *
N.I. PEIZHOU ET AL SYNTHESIS OF 2-(2-METHOXYPHENOXY)ETHYLAMINE page 321 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109206328A (en) * 2018-09-27 2019-01-15 铜仁学院 A kind of preparation method of 2- (2- methoxyphenoxy) ethamine
CN115232034A (en) * 2022-07-29 2022-10-25 上药康丽(常州)药业有限公司 Method for synthesizing tamsulosin hydrochloride
CN115232034B (en) * 2022-07-29 2024-02-20 上药康丽(常州)药业有限公司 Synthesis method of tamsulosin hydrochloride

Also Published As

Publication number Publication date
WO2009128088A3 (en) 2010-12-23

Similar Documents

Publication Publication Date Title
TWI436972B (en) Improved process for the manufacture of r-(+)-2-(4-(4-cyano-2-fluorophenoxy)phenoxy)propionic acid esters
TWI454464B (en) Process for the preparation of piperazine derivatives
US9908894B2 (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
JP5916721B2 (en) Synthetic method of ferroquine by intensive reductive amination
US10800748B2 (en) Process for the manufacture of R-6-hydroxy-8-[1-hydroxy-2-[2-(4-methoxyphenyl)-1,1-dimethylethylaminoethyl]-2H-1,4-benzoxazin-3(4H)-one hydrochloride
WO2009128088A2 (en) Preparation of 2-(2-alkoxy phenoxy) ethylamine, an intermediate of carvedilol and tamsulosin
JP2017521437A (en) Apixaban production method
US20170145001A1 (en) Processes for preparing brexpiprazole
JP2019507156A (en) Process for producing 4-alkoxy-3-hydroxypicolinic acid
EP3356329A1 (en) Process for preparing 1-(4-methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1h-pyrrolo [2,3-b]pyridin-3-yl-acetic acid
JP6228210B2 (en) Method for purifying fluvoxamine free base and method for producing high purity fluvoxamine maleate using the same
US8742103B2 (en) Separation of triazine derivatives enantiomers using tartaric acid
JP2012514005A (en) Synthesis of (2-amino) tetrahydrocarbazole-propanoic acid
JP2020515553A (en) Process for preparing 1-(4-methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl-acetic acid
EP2419407B1 (en) Improved process for the preparation of fluvastatin and salts thereof
JP6943560B2 (en) Method for Producing 2-Amino-6-Methylnicotinic Acid Ester or Protonate thereof
CN104447527A (en) Method for preparing pyridine-2,3-dicarboxylic ester compound
US11161821B2 (en) Process for the preparation of Eltrombopag olamine and its intermediates
CN112759562B (en) Preparation method of high-purity hydrobromic acid vortioxetine
CA2558817A1 (en) Crystalline forms of 5,11-dihydro-11-ethyl-5-methyl-8-{2-{(1-oxido-4-quinolinyl)oxy}ethyl}-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one
WO2009027990A1 (en) Salts of montelukast and process therefor
JP6911015B2 (en) Indane amine derivative manufacturing method and new synthetic intermediates
JP2004315535A (en) Method for preparing hexahydropyridazine-3-carboxylic acid derivative
SK278128B6 (en) Method of preparation of anilinefumarate and from its derived quinoline-2,3-dicarboxylic acid
US20090247581A1 (en) Organic Compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08873943

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08873943

Country of ref document: EP

Kind code of ref document: A2